Erratum: Association of genotypes of the CYP3A cluster with midazolam disposition in vivo (The Pharmacogenomics Journal (2009) 9, (319-326) DOI: 10.1038/tpj.2009.21);Association of genotypes of the CYP3A cluster with midazolam disposition in vivo

Pharmacogenomics Journal

Volumn 9, Issue 5, 2009, Pages 319-326

  Miao, J ^a   Jin, Y ^a   Marunde, R L ^a   Kim, S ^b   Quinney, S ^b   Radovich, M ^a   Li, L ^b   Hall, S D ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; MIDAZOLAM;

AFRICAN AMERICAN; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG METABOLISM; ETHNIC DIFFERENCE; GENE ACTIVITY; GENE CLUSTER; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC TRAIT; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IN VIVO STUDY; META ANALYSIS; PHARMACOGENOMICS; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW;

ADMINISTRATION, ORAL; ADULT; AFRICAN AMERICANS; AGE FACTORS; AGED; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; HAPLOTYPES; HUMANS; INFUSIONS, INTRAVENOUS; LINKAGE DISEQUILIBRIUM; MALE; MIDAZOLAM; MIDDLE AGED; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; SEX FACTORS;

EID: 70349664493     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2010.63     Document Type: Erratum

References (49)

1. Guengerich FP. Cytochrome P-450 3A4: Regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999; 39: 1-17.
2. Evans WE, Relling MV. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 1999; 286: 487-491.
3. Chen M, Nafziger AN, Bertino Jr JS. Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam. Drug Metab Dispos 2006; 34: 2079-2082.
4. Wojnowski L, Kamdem LK. Clinical implications of CYP3A polymorphisms. Expert Opin Drug Metab Toxicol 2006; 2: 171-182.
5. Ball SE, Scatina J, Kao J, Ferron GM, Fruncillo R, Mayer P et al. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther 1999; 66: 288-294.
6. Thompson EE, Kuttab-Boulos H, Witonsky D, Yang L, Roe BA, Di Rienzo A. CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet 2004; 75: 1059-1069.
7. Burk O, Tegude H, Koch I, Hustert E, Wolbold R, Glaeser H et al. Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J Biol Chem 2002; 277: 24280-24288.
8. Thompson EE, Kuttab-Boulos H, Yang L, Roe BA, Di Rienzo A. Sequence diversity and haplotype structure at the human CYP3A cluster. Pharmacogenomics J 2006; 6: 105-114.
9. Garcia-Martin E, Martinez C, Pizarro RM, Garcia-Gamito FJ, Gullsten H, Raunio H et al. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin Pharmacol Ther 2002; 71: 196-204.
10. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR. CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism. Clin Pharmacol Ther 2000; 68: 82-91.
11. Rodriguez-Antona C, Sayi JG, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M. Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun 2005; 338: 299-305.
12. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-391.
13. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11: 773-779.
14. Jin Y, Wang YH, Miao J, Li L, Kovacs RJ, Marunde R et al. Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects. Clin Pharmacol Ther 2007; 82: 579-585.
15. Dally H, Edler L, Jager B, Schmezer P, Spiegelhalder B, Dienemann H et al. The CYP3A4*1B allele increases risk for small cell lung cancer: Effect of gender and smoking dose. Pharmacogenetics 13 2003: 607-618.
16. Wojnowski L, Hustert E, Klein K, Goldammer M, Haberl M, Kirchheiner J et al. Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 2002; 94: 630-631; author reply 1-2.
17. Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 2002; 34: 47-54.
18. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ et al Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999; 16: 408-414.
19. Masica AL, Mayo G, Wilkinson GR. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. Clin Pharmacol Ther 2004; 76: 341-349.
20. Krupka E, Venisse N, Lafay C, Gendre D, Diquet B, Bouquet S et al. Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers. Eur J Clin Pharmacol 2006; 62: 653-659.
21. Lee J-I, Chaves-Gnecco D, Amico JA, Kroboth PD, Wilson JW, Frye RF. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther 2002; 72: 718-728.
22. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. [erratum appears in Drug Metab Dispos 1995 Mar;23(3): followi]. Drug Metab Dispos 1994; 22: 947-955.
23. Liu YT, Hao HP, Liu CX, Wang GJ, Xie HG. Drugs as CYP3A probes, inducers, and inhibitors. Drug Metab Rev 2007; 39: 699-721.
24. Lee LS, Bertino Jr JS, Nafziger AN. Limited sampling models for oral midazolam: Midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activity. J Clin Pharmacol 2006; 46: 229-234.
25. Streetman DS, Bertino Jr JS, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: A review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000; 10: 187-216.
26. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD et al Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996; 59: 491-502.
27. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara Jr EM, Hall SD. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998; 64: 133-143.
28. Eap CB, Buclin T, Hustert E, Bleiber G, Golay KP, Aubert A-C et al Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. Eur J Clin Pharmacol 2004; 60: 231-236.
29. Floyd MD, Gervasini G, Masica AL, Mayo G, George Jr AL, Bhat K et al Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.[see comment]. Pharmacogenetics 2003; 13: 595-606.
30. Shih P-S, Huang J-D. Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos 2002; 30: 1491-1496.
31. Chen M, Ma L, Drusano GL, Bertino Jr JS, Nafziger AN. Sex differences in CYP3A activity using intravenous and oral midazolam. Clin Pharmacol Ther 2006; 80: 531-538.
32. Greenblatt DJ, Harmatz JS, von Moltke LL, Wright CE, Shader RI. Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate. Clin Pharmacol Ther 2004; 76: 467-479.
33. Wolbold R, Klein K, Burk O, Nussler AK, Neuhaus P, Eichelbaum M et al Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 2003; 38: 978-988.
34. Gorski JC, Wang Z, Haehner-Daniels BD, Wrighton SA, Hall SD. The effect of hormone replacement therapy on CYP3A activity. Clin Pharmacol Ther 2000; 68: 412-417.
35. Carrillo JA, Ramos SI, Agundez JA, Martinez C, Benitez J. Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography: Probe of CYP3A. Ther Drug Monit 1998; 20: 319-324.
36. Tateishi T, Watanabe M, Nakura H, Asoh M, Shirai H, Mizorogi Y et al CYP3A activity in European American and Japanese men using midazolam as an in vivo probe. Clin Pharmacol Ther 2001; 69: 333-339.
37. Kalow W, Ozdemir V, Tang BK, Tothfalusi L, Endrenyi L. The science of pharmacological variability: An essay. Clin Pharmacol Ther 1999; 66: 445-447.
38. Ozdemir V, Kalow W, Tang BK, Paterson AD, Walker SE, Endrenyi L et al Evaluation of the genetic component of variability in CYP3A4 activity: A repeated drug administration method. Pharmacogenetics 2000; 10: 373-388.
39. Xie H-G, Wood AJJ, Kim RB, Stein CM, Wilkinson GR. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004; 5: 243-272.
40. Lee S-J, Goldstein JA. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. Pharmacogenomics 2005; 6: 357-371.
41. Mirghani RA, Sayi J, Aklillu E, Allqvist A, Jande M, Wennerholm A et al. CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. Pharmacogenet Genomics 2006; 16: 637-645.
42. Pinto AG, Wang Y-H, Chalasani N, Skaar T, Kolwankar D, Gorski JC et al. Inhibition of human intestinal wall metabolism by macrolide antibiotics: Effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin Pharmacol Ther 2005; 77: 178-188.
43. He P, Court MH, Greenblatt DJ, Von Moltke LL. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.[see comment]. Clin Pharmacol Ther 2005; 77: 373-387.
44. Kharasch ED, Walker A, Isoherranen N, Hoffer C, Sheffels P, Thummel K et al. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther 2007; 82: 410-426.
45. Kashuba AD, Bertino Jr JS, Rocci Jr ML, Kulawy RW, Beck DJ, Nafziger AN. Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. Clin Pharmacol Ther 1998; 64: 269-277.
46. Zhu B, Liu Z-Q, Chen G-L, Chen X-P, Ou-Yang D-S, Wang L-S et al. The distribution and gender difference of CYP3A activity in Chinese subjects. Br J Clin Pharmacol 2003; 55: 264-269.
47. Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 1984; 61: 27-35.
48. Quinney SK, Haehner BD, Rhoades MB, Lin Z, Gorski JC, Hall SD. Interaction between midazolam and clarithromycin in the elderly. Br J Clin Pharmacol 2008; 65: 98-109.
49. Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B et al. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther 2003; 74: 275-287.